Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-08-14
2008-12-30
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S291000
Reexamination Certificate
active
07470682
ABSTRACT:
Compounds of the following structure, wherein R1, R2, R4, R4′, R6, R7, and R15are defined above, are provided:These compounds are useful in treating neurological disorders or complications due to stroke or head injury. The compounds are therefore useful as neuroprotective and neuroregenerative agents.
REFERENCES:
patent: 3491092 (1970-01-01), Grignat et al.
patent: 3686238 (1972-08-01), Zaffaroni et al.
patent: 3738980 (1973-06-01), Bickel et al.
patent: 3900465 (1975-08-01), Cricchio et al.
patent: 3905981 (1975-09-01), Olofson et al.
patent: 4127720 (1978-11-01), Juby et al.
patent: 5023262 (1991-06-01), Caufield et al.
patent: 5525610 (1996-06-01), Caufield et al.
patent: 5604294 (1997-02-01), Luly et al.
patent: 5696135 (1997-12-01), Steiner et al.
patent: 5717092 (1998-02-01), Armistead et al.
patent: 5780484 (1998-07-01), Zelle et al.
patent: 5798355 (1998-08-01), Steiner et al.
patent: 6015809 (2000-01-01), Zhu et al.
patent: 6187784 (2001-02-01), Steiner et al.
patent: 6500843 (2002-12-01), Steiner et al.
patent: 6624302 (2003-09-01), Chu et al.
patent: 7273874 (2007-09-01), Graziani et al.
patent: 7276498 (2007-10-01), Graziani et al.
patent: 2001/0036947 (2001-11-01), Steiner et al.
patent: 2002/0151088 (2002-10-01), Molnar-Kimber et al.
patent: 2004/0224394 (2004-11-01), Katz et al.
patent: 2007/0142423 (2007-06-01), Graziani et al.
patent: 2007/0213525 (2007-09-01), Graziani et al.
patent: 9516257 (1995-10-01), None
patent: 1445742 (1968-12-01), None
patent: 1545824 (1969-12-01), None
patent: 4021404 (1992-01-01), None
patent: 0343560 (1989-11-01), None
patent: 0 475 577 (1991-08-01), None
patent: 0778023 (1997-06-01), None
patent: 2249027 (1992-04-01), None
patent: 08333256 (1996-12-01), None
patent: WO-91/19495 (1991-12-01), None
patent: WO-92/13862 (1992-08-01), None
patent: WO-93/04679 (1993-03-01), None
patent: WO-93/04680 (1993-03-01), None
patent: WO-94/02136 (1994-02-01), None
patent: WO-94/02485 (1994-02-01), None
patent: WO-94/25022 (1994-11-01), None
patent: WO-96/40140 (1996-12-01), None
patent: WO-99/62483 (1999-12-01), None
patent: WO-00/09109 (2000-02-01), None
patent: WO-00/09510 (2000-02-01), None
patent: WO-00/34239 (2000-06-01), None
patent: WO-01/18006 (2001-03-01), None
patent: WO-01/34816 (2001-05-01), None
patent: WO-01/87884 (2001-11-01), None
patent: WO-03/018573 (2003-03-01), None
patent: WO-03/018574 (2003-03-01), None
patent: WO-2004/007709 (2004-01-01), None
Cantley et al., “New Insights into Tumor Suppression: PTEC Suppresses Tumor Formation by Restraining the Phosphoinositide 3-Kinase/AKT Pathway” Proc. Natl. Acad. Sci. USA, 96:4240-4245 (Apr. 1999).
Ali et al., “Mutational Spectra of PTEN/MMAC1 Gene: A Tumor Suppressor with Lipid Phosphatase Activity” J. Natl. Cancer. Inst., 91(22):1922 (Nov. 17, 1999).
Nave et al., “Mammalian Target of Rapamycin is a Direct Target for Protein Kinase B: Identification of a Convergence Point for Opposing Effects of Insulin and Amino-Acid Deficiency on Protein Translation” Biochem. J. 344:427-431 (Dec. 1, 1999).
Scott et al., “Evidence of Insulin-Stimulated Phosphorylation and Activation of the Mammalian Target of Rapamycin Mediated by a Protein Kinase B Signaling Pathway” Proc. Nat. Acad. Sci. USA, 95:7772-7777 (Jun. 1998).
Steiner et al., Neurotrophic Actions on Nonimmunosuppressive Analogues of Immunosuppressive Drugs FK506, Rapamycin and Cyclosporin Nat. Med., 3(4):421 (Apr. 1997).
Gold et al., “Neuroimmunophilin Ligands: The Development of Novel Neuroregenerative/Neuroprotective Compounds”, Curr. Topics Med. Chem., 3:1368 (2003).
Birge et al., “A Role for Schwann Cells in the Neuroregenerative Effects of a Non-Immunosuppressive FK506 Derivative, JNJ460”, Neuroscience, 124:351-366 (2004).
Tanaka et al., “Possibility of Non-Immunosuppressive Immunophilin Ligands as Potential Therapeutic Agents for Parkinson's Disease” Curr. Pharm. Design, 10:669-677 (2004).
Pong et al., “Therapeutic Implications for Immunophilin Ligands in the Treatment of Neurodegenerative Diseases” Curr. Drug Targets—CNS & Neurolog. Disorders, 2(6):349 (Dec. 2003).
Ocain et al., “A Nonimmunosuppressive Triene-Modified Rapamycin Analog is a Potent Inhibitor of Peptidyl Prolyl Cis-Trans Isomerase”, Biochem. Biophys. Rse. Commun. 192(3):1340 (May 14, 1993).
Dickman et al., “Antifungal Rapamycin Analogues with Reduced Immunosuppressive Activity”, Bioorg. & Med. Chem. Lett. 10(13):1405-1408 (Jul. 3, 2000).
Li et al., “Analysis of the Energetics of Gas-Phase Immunophilin-Ligand Complexes by Ion Spray Mass Spectrometry”, J. Am. Chem. Soc., 116(17):7487 (1994).
Grigat et al., “2-Sulphonamido- and 2-Sulphonylhydrazido-benzoxazinones”, English language Abstract of DE 1,545,824.
Nussbaumer et al., “New Tricyclic Heteroatom Containing Compounds for Arthritis”, English language Abstract of DE 4,021,404.
Snyder et al, Immunophilins and the Nervous System, Nature Medicine, vol. 1, No. 1, pp. 32-37, (Jan. 1995).
Holt et al, Structure-Activity Studies of Synthetic FKBP Ligands as Peptidyl-Prolyl Isomerase Inhibitors, Biorganic & Medicinal Chemistry Letters, vol. 4, No. 2, pp. 315-320, (1994).
Graziani Edmund Idris
Pong Kevin
Skotnicki Jerauld
Kifle Bruck
Wyeth
LandOfFree
Rapamycin analogues and the uses thereof in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rapamycin analogues and the uses thereof in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rapamycin analogues and the uses thereof in the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4024721